Browse Items (2 total)

Tags: Head & neck

Sort by:

Vocal cord paralysis from prostatic carcinoma metastasizing to the larynx.

According to 1992 Cancer Statistics, prostate carcinoma is once again predicted to be the most common cancer in men, exceeding the incidence of lung cancer. In American men, this cancer is estimated to be the second most frequent cause of cancer…

Tags: 1993, Adenocarcinoma/*pathology/*secondary, Aged, Head & neck, Humans, Laryngeal Neoplasms/*secondary, Male, Park M H, Park Y W, Prostatic Neoplasms/*pathology, Thyroid Cartilage/pathology, Vocal Cord Paralysis/*etiology

Phase II study of gefitinib in patients with advanced salivary gland cancers.

BACKGROUND: The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: We conducted a phase II study in…

Tags: 2015, 80 and over, Adenocarcinoma/drug therapy/mortality/pathology, adenoid cystic carcinoma, Adenoid Cystic/*drug therapy/mortality/pathology, Adult, Aged, Antineoplastic Agents/*therapeutic use, Blumenschein George R Jr, Carcinoma, Department of Internal Medicine, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, El-Naggar Adel K, Female, Gefitinib, Glisson Bonnie S, Gonzalez-Angulo Ana M, Head & neck, Humans, Jakob John A, Kies Merrill S, Kupferman Michael E, Lee J Jack, Liu Diane D, Local/*drug therapy/mortality/pathology, Male, Maximum Tolerated Dose, Middle Aged, NEOMED College of Medicine, Neoplasm Invasiveness/pathology, Neoplasm Recurrence, Neoplasm Staging, non-adenoid cystic carcinoma, Prognosis, Quinazolines/*therapeutic use, Remission Induction, response to therapy, salivary gland cancer, Salivary Gland Neoplasms/*drug therapy/mortality/pathology, Survival Analysis, Treatment Outcome

Output Formats

atom, dcmes-xml, json, omeka-xml, rss2